MCID: HYP602
MIFTS: 31

Hyperoxaluria, Primary, Type Ii malady

Categories: Genetic diseases, Rare diseases, Nephrological diseases, Metabolic diseases, Eye diseases

Aliases & Classifications for Hyperoxaluria, Primary, Type Ii

About this section

Aliases & Descriptions for Hyperoxaluria, Primary, Type Ii:

Name: Hyperoxaluria, Primary, Type Ii 51 24 12 49
D-Glycerate Dehydrogenase Deficiency 23 47 24 53 69
Glyoxylate Reductase/hydroxypyruvate Reductase Deficiency 23 47 24 69
Primary Hyperoxaluria Type 2 23 47 53 67
L-Glyceric Aciduria 23 24 53 69
Primary Hyperoxaluria Type Ii 69 26
Glyceric Aciduria 47 69
Hp2 47 69
 
Glyoxylate Reductase/hydroxypyruvate Reductase 12
Glyoxylate Reductase Deficiency 24
Hyperoxaluria, Primary, Type 2 24
Hyperoxaluria Primary Type Ii 69
Hyperoxaluria Primary 2 69
Oxalosis Ii 69
Oxalosis 2 47
Ph2 69

Characteristics:

Orphanet epidemiological data:

53
d-glycerate dehydrogenase deficiency:
Inheritance: Autosomal recessive; Age of onset: Childhood; Age of death: any age

HPO:

63
hyperoxaluria, primary, type ii:
Inheritance: autosomal recessive inheritance

Classifications:



External Ids:

OMIM51 260000
Orphanet53 ORPHA93599
ICD10 via Orphanet30 E74.8
MedGen36 C0268165
MeSH38 D006960

Summaries for Hyperoxaluria, Primary, Type Ii

About this section
NIH Rare Diseases:47 Primary hyperoxaluria type 2  is a rare condition characterized by the overproduction of a substance called oxalate (also called oxalic acid). In the kidneys, the excess oxalate combines with calcium to form calcium oxalate, a hard compound that is the main component of kidney stones. Deposits of calcium oxalate can lead to kidney damage, kidney failure, and injury to other organs. Primary hyperoxaluria type 2 is caused by the shortage (deficiency) of an enzyme called glyoxylate reductase/hydroxypyruvate reductase (GRHPR) that normally prevents the buildup of oxalate. This enzyme shortage is caused by mutations in the GRHPR gene. Primary hyperoxaluria type 2 is inherited in an autosomal recessive pattern. Last updated: 1/3/2013

MalaCards based summary: Hyperoxaluria, Primary, Type Ii, also known as d-glycerate dehydrogenase deficiency, is related to d-glyceric aciduria and primary hyperoxaluria, and has symptoms including renal insufficiency, nephrocalcinosis and hematuria. An important gene associated with Hyperoxaluria, Primary, Type Ii is GRHPR (Glyoxylate And Hydroxypyruvate Reductase). Affiliated tissues include kidney and endothelial.

UniProtKB/Swiss-Prot:69 Hyperoxaluria primary 2: A disorder characterized by elevated urinary excretion of oxalate and L-glycerate, progressive tissue accumulation of insoluble calcium oxalate, nephrolithiasis, nephrocalcinosis, and end-stage renal disease.

Description from OMIM:51 260000

GeneReviews for NBK2692

Related Diseases for Hyperoxaluria, Primary, Type Ii

About this section

Diseases in the Primary Hyperoxaluria family:

Hyperoxaluria, Primary, Type 1 hyperoxaluria, primary, type ii
Hyperoxaluria, Primary, Type Iii

Diseases related to Hyperoxaluria, Primary, Type Ii via text searches within MalaCards or GeneCards Suite gene sharing:

idRelated DiseaseScoreTop Affiliating Genes
1d-glyceric aciduria12.5
2primary hyperoxaluria11.4
3d-glycericacidemia11.0
4hyperoxaluria, primary, type 110.9
5end stage renal failure9.9
6nephrocalcinosis9.9
7malaria9.9

Graphical network of diseases related to Hyperoxaluria, Primary, Type Ii:



Diseases related to hyperoxaluria, primary, type ii

Symptoms for Hyperoxaluria, Primary, Type Ii

About this section

Symptoms by clinical synopsis from OMIM:

260000

Clinical features from OMIM:

260000

Human phenotypes related to Hyperoxaluria, Primary, Type Ii:

 63 (show all 6)
id Description HPO Frequency HPO Source Accession
1 renal insufficiency63 rare (5%) HP:0000083
2 nephrocalcinosis63 HP:0000121
3 hematuria63 HP:0000790
4 hyperoxaluria63 HP:0003159
5 aminoaciduria63 HP:0003355
6 calcium oxalate nephrolithiasis63 HP:0008672

Drugs & Therapeutics for Hyperoxaluria, Primary, Type Ii

About this section

Drugs for Hyperoxaluria, Primary, Type Ii (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 21)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Vitamin Eapproved, nutraceutical, vet_approvedPhase 2, Phase 340659-02-914985
Synonyms:
(+)-a-Tocopherol
(+)-alpha-Tocopherol
(+)-α-tocopherol
(2R)-2,5,7,8-TETRAMETHYL-2-[(4R,8R)-4,8,12-TRIMETHYLTRIDECYL]CHROMAN-6-OL
(2R)-3,4-Dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-ol
(2R,4'R,8'R)-a-Tocopherol
(2R,4'R,8'R)-alpha-Tocopherol
(2R,4'R,8'R)-α-tocopherol
(R,R,R)-a-Tocopherol
(R,R,R)-alpha-Tocopherol
(R,R,R)-α-tocopherol
5,7,8-Trimethyltocol
5,7,8-trimethyltocol
Amino-Opti-E
Aquasol E
D-alpha-Tocopherol
Daltose
Denamone
E-200 I.U. Softgels
 
E-Complex-600
E-Ferol
E-Vitamin succinate
Eprolin
Gordo-Vite E
Phytogermin
Phytogermine
RRR-alpha-tocopherol
RRR-alpha-tocopheryl
Tocopherol
Vitamin E
Vitamin Ea
Vitamin Plus E Softgells
Vitec
a-D-Tocopherol
a-Tocopherol
alpha-Tocopherol
alpha-delta-Tocopherol
alpha-tocopherol
d-α-tocopherol
delta-alpha-Tocopherol
2TocotrienolsPhase 2, Phase 3402
3Trace ElementsPhase 2, Phase 35802
4VitaminsPhase 2, Phase 35095
5AntioxidantsPhase 2, Phase 32928
6MicronutrientsPhase 2, Phase 35802
7Protective AgentsPhase 2, Phase 37190
8TocopherolsPhase 2, Phase 3406
9TocotrienolNutraceuticalPhase 2, Phase 3402
10TocopherolNutraceuticalPhase 2, Phase 3406
11
Vorinostatapproved, investigationalPhase 2242149647-78-95311
Synonyms:
149647-78-9
1zz1
AC-1923
AC1L1K2K
BRD-K81418486-001-10-3
C111237
CCRIS 8456
CHEBI:45716
CHEMBL98
CID5311
D06320
DB02546
EC-000.2057
FT-0082592
LS-186548
LS-186997
LS-187780
MK-0683
MK0683
MLS001065855
Merck brand of Vorinostat
MolPort-003-850-293
N'-hydroxy-N-phenyloctanediamide
N-Hydroxy-N'-phenyl octanediamide
N-Hydroxy-N'-phenyloctanediamide
N-Hyrdroxy-N'-phenyloctanediamide
N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide
N-hydroxy-N'-phenyloctanediamide
N1-hydroxy-N8-phenyloctanediamide
NCGC00168085-02
 
NHNPODA
NSC-701852
NSC701852
OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE
Octanedioic acid hydroxyamide phenylamide
S1047_Selleck
SAHA
SAHA cpd
SAHA, Suberoylanilide hydroxamic acid
SHH
SKI390
SMR000486344
SW-064652
Suberanilohydroxamic acid
SuberoylaN/Aide hydroxamic acid
Suberoylanilide hydroxamic acid
UNII-58IFB293JI
Vorinostat
Vorinostat (JAN/USAN)
Vorinostat MSD
Vorinostat [USAN]
Vorinostatum
WIN64652
ZINC01543873
Zolinza
Zolinza (TN)
Zolinza, MK-0683, SAHA
m344
nchembio.275-comp2
nchembio.313-comp1
nchembio815-comp18
suberoylanilide hydroxamic acid
12Histone Deacetylase InhibitorsPhase 2566
13
Ironapproved11237439-89-623925
Synonyms:
02583_FLUKA
12310_ALDRICH
12310_RIEDEL
129048-51-7
14067-02-8
161135-39-3
190454-13-8
195161-83-2
199281-22-6
209309_ALDRICH
209309_SIAL
255637_ALDRICH
266213_ALDRICH
266256_ALDRICH
267945_ALDRICH
267953_ALDRICH
26Fe
338141_ALDRICH
356808_ALDRICH
356824_ALDRICH
356832_ALDRICH
39344-71-3
3ZhP
413054_ALDRICH
443783-52-6
44890_ALDRICH
44890_FLUKA
675141-17-0
70884-35-4
73135-38-3
7439-89-6
8011-79-8
8053-60-9
AC1L2N38
ATW 230
ATW 432
Ancor B
Ancor en 80/150
Armco iron
Atomel 28
Atomel 300M200
Atomel 500M
Atomel 95
Atomiron 44MR
Atomiron 5M
Atomiron AFP 25
Atomiron AFP 5
C00023
C3518_SIAL
C3518_SIGMA
CCRIS 1580
CHEBI:18248
CID23925
Carbonyl iron
Copy Powder CS 105-175
D007501
DB01592
DSP 1000
DSP 128B
DSP 135
DSP 135C
DSP 138
Diseases (animal), iron overload
Diseases, iron overload
EF 1000
EF 250
EFV 200/300
EFV 250
EFV 250/400
EINECS 231-096-4
 
Ed-In-Sol
Eisen
Electrolytic iron
F 60 (metal)
FE
FT 3 (element)
Fe
Fe-40
Fe1+
Feronate
Ferretts
Ferro-Caps
Ferro-Time
Ferrousal
Ferrovac E
Ferrum
Ferrum metallicum
GS 6
HF 2 (element)
HL (iron)
HQ (metal)
HS (iron)
HS 4849
HSDB 604
Hemocyte
Hierro
Hoeganaes ATW 230
Hoeganaes EH
IRMM524A_FLUKA
IRMM524B_FLUKA
IRON
Iron (Fe)
Iron (Fe1+)
Iron ion (Fe+)
Iron ion(1+)
Iron monocation
Iron powder
Iron standard for AAS
Iron(1+)
Iron(1+) ion
Iron(III) nitrate solution
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (Fe1+)
Iron, ion (Fe1+) (8CI,9CI)
Iron, reduced
LOHA
LS-3196
MolPort-003-925-001
NC 100
PZh-1M3
PZh-2
PZh1M1
PZh2M
PZh2M1
PZh2M2
PZh3
PZh3M
PZh4M
PZhO
Reduced iron
Remko
SUY-B 2
Siderol
UNII-E1UOL152H7
Vitedyn-Slo
Yieronia
fer
ferrous iron
hierro
14
Temazepamapproved27846-50-45391
Synonyms:
1,3-Dihydro-7-chloro-3-hydroxy-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one
3 Hydroxydiazepam
3-Hydroxydiazepam
5-25-02-00242 (Beilstein Handbook Reference)
7-CHLORO-1,3-DIHYDRO-3-HYDROXY-1-METHYL-5-PHENYL-2H-1,4-BENZODIAZEPIN-2-ONE
7-Chloro-3-hydroxy-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one
7-chloro-3-hydroxy-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one
846-50-4
AC1L1K92
AHP Brand of Temazepam
Alphapharm Brand of Temazepam
Apo Temazepam
Apo-Temazepam
Apotex Brand of Temazepam
BRN 0759300
CCRIS 1954
CHEMBL967
CID5391
Cerepax
Crisonar
D00370
D013693
DB00231
DEA No. 2925
Dasuen
Desitin Brand of Temazepam
DivK1c_000989
EINECS 212-688-1
ER 115
Euhypnos
Euipnos
Gelthix
Gen Temazepam
Gen-Temazepam
Genopharm Brand of Temazepam
Genpharm Brand of Temazepam
HMS503E19
Hydroxydiazepam
ICN Brand of Temazepam
IDI1_000989
K-3917
K3917
KBio1_000989
Katwijk Brand of Temazepam
Knoll Brand of Temazepam
LS-7712
Lenal
Levanxene
Levanxol
Levanzene
Mabertin
Mallinckrodt Brand of Temazepam
Methyloxazepam
MolPort-002-051-814
N-Methyloxazepam
NCGC00159440-02
NINDS_000989
NSC 246303
NSC246303
Neodorm SP
Nocturne
 
Nomapam
Norkotral Tema
Normison
Normitab
Nortem
Norton Brand of Temazepam
Novartis Brand of Temazepam
Novo Temazepam
Novo-Temazepam
Novopharm Brand of Temazepam
Nu Pharm Brand of Temazepam
Nu Temazepam
Nu-Pharm Brand of Temazepam
Nu-Temazepam
Orion Brand of Temazepam
Oxydiazepam
PMS Temazepam
PMS-Temazepam
Perdorm
Pfizer Brand 1 of Temazepam
Pfizer Brand 2 of Temazepam
Pharmascience Brand of Temazepam
Planum
Pronervon T
Remestan
Restoril
Restoril (TN)
Ro 5 5345
Ro 5-5345
Ro-5-5345
Ro55345
SaH 47 603
SaH 47-603
SaH 47603
Scheffler Brand of Temazepam
Sigma Brand of Temazepam
Signopam
T8275_FLUKA
T8275_SIGMA
Tema, Norkotral
Temador
Temaz
Temaze
Temazepam (USP/INN)
Temazepam [USAN:INN:BAN]
Temazepam, pharmaceutical grade
Temazepamum
Temazepamum [INN-Latin]
Temtabs
Tenox
UNII-CHB1QD2QSS
Uvamin Retard
WLN: T67 GNV JN IHJ CG G1 IQ KR
WY 2917
WY 3917
WY3917
Wy-3917
Wyeth Brand of Temazepam
ct Arzneimittel Brand of Temazepam
ct-Arzneimittel Brand of Temazepam
temazep von ct
temazepam
15Antibiotics, Antitubercular6972
16Anti-Bacterial Agents10884
17Hematinics1630
18ferric gluconate19
19carnitineNutraceutical158
20lysineNutraceutical90
21methionineNutraceutical80

Interventional clinical trials:

(show all 21)
idNameStatusNCT IDPhase
1Endothelial Function in a Sample Group of Patients From the ICARE StudyCompletedNCT00314379Phase 2, Phase 3
2Phase 2/3 Oxabact StudyCompletedNCT01037231Phase 2, Phase 3
3Renal Protective Effect of ACEI and ARB in Primary HyperoxaluriaWithdrawnNCT00280215Phase 3
4Vorinostat in Treating Patients With Metastatic or Unresectable MelanomaCompletedNCT00121225Phase 2
5Primary Hyperoxaluria Mutation GenotypingCompletedNCT00589225Phase 1
6The Type of Hepatoglobin in IUGRUnknown statusNCT02127385
7Cognitive Dysfunction in People Who Are Obese But Metabolically HealthyUnknown statusNCT01928355
8Effect of a Novel Nutraceutical on Weight Loss and Weight Maintenance in Obese SubjectsUnknown statusNCT01656681
9Epidemiology of Papillomavirus Infection (HPV) on Infected Women by Human Immunodeficience Virus (HIV) in West Indies and French Guiana.CompletedNCT01226368
10Prevalence of Different Haptoglobin Phenotypes in Patients With COPD- Frequent Exacerbators Versus Non ExacerbatorsCompletedNCT01745419
11Haptoglobin Phenotype and Cardiovascular Complications in Diabetic PatientsCompletedNCT00448487
12Effect of Sleep Apnea Treatment on Type 1 DiabetesCompletedNCT02316665
13Relationship of Haptoglobin Phenotype to Vascular Function and Response to Vitamin E Supplementation in Patients With Diabetes Mellitus Type 2: The EVAS TrialRecruitingNCT02776397
14Haptoglobin and Diabetes Complications in PregnancyRecruitingNCT01758016
15Effects of Carnitine on Oxidative Stress to IVIR Administration to CKD Patients:Impact of Haptoglobin GenotypeRecruitingNCT02312414
16Severe Obesity Outcome Network CohortRecruitingNCT02264431
17Rare Kidney Stone Consortium BiobankRecruitingNCT02026388
18Primary Hyperoxaluria Mutation Genotyping/PhenotypingRecruitingNCT02340689
19Prospective Research Rare Kidney Stones (ProRKS)RecruitingNCT02780297
20Associations Between Diabetes Care and Haptoglobin Genotype On outComesActive, not recruitingNCT00872456
21International Registry for Primary HyperoxaluriaWithdrawnNCT00875823

Search NIH Clinical Center for Hyperoxaluria, Primary, Type Ii

Genetic Tests for Hyperoxaluria, Primary, Type Ii

About this section

Genetic tests related to Hyperoxaluria, Primary, Type Ii:

id Genetic test Affiliating Genes
1 Primary Hyperoxaluria, Type Ii26
2 Hyperoxaluria, Primary, Type 224 GRHPR

Anatomical Context for Hyperoxaluria, Primary, Type Ii

About this section

MalaCards organs/tissues related to Hyperoxaluria, Primary, Type Ii:

35
Kidney, Endothelial

Animal Models for Hyperoxaluria, Primary, Type Ii or affiliated genes

About this section

Publications for Hyperoxaluria, Primary, Type Ii

About this section

Variations for Hyperoxaluria, Primary, Type Ii

About this section

Clinvar genetic disease variations for Hyperoxaluria, Primary, Type Ii:

5 (show all 40)
id Gene Variation Type Significance SNP ID Assembly Location
1GRHPRNM_012203.1(GRHPR): c.864_865delTG (p.Val289Aspfs)deletionLikely pathogenic, Pathogenicrs180177321GRCh37Chr 9, 37432134: 37432135
2GRHPRNM_012203.1(GRHPR): c.248_249delTG (p.Val83Glyfs)deletionPathogenicrs672601351GRCh38Chr 9, 37425955: 37425956
3GRHPRNM_012203.1(GRHPR): c.904C> T (p.Arg302Cys)SNVPathogenicrs180177322GRCh37Chr 9, 37436696: 37436696
4GRHPRNM_012203.1(GRHPR): c.337G> A (p.Glu113Lys)SNVLikely pathogenic, Pathogenicrs180177307GRCh38Chr 9, 37426587: 37426587
5GRHPRNM_012203.1(GRHPR): c.-4_-3delGCinsATindelPathogenicrs796052077GRCh37Chr 9, 37422744: 37422745
6GRHPRNM_012203.1(GRHPR): c.102G> A (p.Trp34Ter)SNVPathogenicrs180177304GRCh37Chr 9, 37424860: 37424860
7GRHPRNM_012203.1(GRHPR): c.203T> C (p.Leu68Pro)SNVPathogenicrs180177305GRCh37Chr 9, 37424961: 37424961
8GRHPRNM_012203.1(GRHPR): c.287G> T (p.Arg96Leu)SNVPathogenicrs796052078GRCh37Chr 9, 37425991: 37425991
9GRHPRNM_012203.1(GRHPR): c.478G> A (p.Gly160Arg)SNVPathogenicrs180177312GRCh37Chr 9, 37428554: 37428554
10GRHPRNM_012203.1(GRHPR): c.494G> A (p.Gly165Asp)SNVPathogenicrs180177314GRCh37Chr 9, 37429729: 37429729
11GRHPRNM_012203.1(GRHPR): c.743T> A (p.Val248Asp)SNVPathogenicrs796052079GRCh37Chr 9, 37432013: 37432013
12GRHPRNM_012203.1(GRHPR): c.905G> A (p.Arg302His)SNVPathogenicrs180177323GRCh38Chr 9, 37436700: 37436700
13GRHPRNM_012203.1(GRHPR): c.934A> G (p.Asn312Asp)SNVPathogenicrs180177324GRCh38Chr 9, 37436729: 37436729
14GRHPRNM_012203.1(GRHPR): c.965T> G (p.Met322Arg)SNVPathogenicrs180177325GRCh37Chr 9, 37436757: 37436757
15GRHPRNM_012203.1(GRHPR): c.965T> C (p.Met322Thr)SNVPathogenicrs180177325GRCh37Chr 9, 37436757: 37436757
16GRHPRNM_012203.1(GRHPR): c.84-2A> GSNVPathogenicrs180177319GRCh37Chr 9, 37424840: 37424840
17GRHPRNM_012203.1(GRHPR): c.493+2T> ASNVLikely pathogenic, Pathogenicrs180177313GRCh37Chr 9, 37428571: 37428571
18GRHPRNM_012203.1(GRHPR): c.735-1G> ASNVLikely pathogenic, Pathogenicrs180177317GRCh37Chr 9, 37432004: 37432004
19GRHPRNM_012203.1(GRHPR): c.45delA (p.Ala17Profs)deletionPathogenicrs180177311GRCh37Chr 9, 37422792: 37422792
20GRHPRNM_012203.1(GRHPR): c.288-2_288delAGTdeletionPathogenicrs796052081GRCh37Chr 9, 37426533: 37426535
21GRHPRNG_008135.1insertionPathogenicChr na, -1: -1
22GRHPRNM_012203.1(GRHPR): c.375delG (p.Leu126Cysfs)deletionPathogenicrs180177308GRCh37Chr 9, 37426622: 37426622
23GRHPRNM_012203.1(GRHPR): c.404+3_404+6delAAGTdeletionLikely pathogenic, Pathogenicrs180177309GRCh37Chr 9, 37426654: 37426657
24GRHPRNM_012203.1(GRHPR): c.540delT (p.Leu181Cysfs)deletionPathogenicrs180177315GRCh37Chr 9, 37429775: 37429775
25GRHPRNM_012203.1(GRHPR): c.608_609delCT (p.Pro203Argfs)deletionPathogenicrs180177316GRCh37Chr 9, 37430517: 37430518
26GRHPRNM_012203.1(GRHPR): c.694delC (p.Gln232Argfs)deletionPathogenicrs796052082GRCh38Chr 9, 37430606: 37430606
27GRHPRNM_012203.1: c.597delTdeletionLikely pathogenicChr na, -1: -1
28GRHPRNM_012203.1: c.404delAdeletionLikely pathogenicChr na, -1: -1
29GRHPRNM_012203.1: c.755dupAduplicationLikely pathogenicChr na, -1: -1
30GRHPRNM_012203.1: c.954delAdeletionLikely pathogenicChr na, -1: -1
31GRHPRNM_012203.1: c.454dupAduplicationLikely pathogenicChr na, -1: -1
32GRHPRNM_012203.1: c.515delTdeletionLikely pathogenicChr na, -1: -1
33GRHPRNM_012203.1: c.441_442delTGdeletionLikely pathogenicChr na, -1: -1
34GRHPRNM_012203.1: c.154delGdeletionLikely pathogenicChr na, -1: -1
35GRHPRNM_012203.1: c.228dupAduplicationLikely pathogenicChr na, -1: -1
36GRHPRNM_012203.1: c.435_436delGCdeletionLikely pathogenicChr na, -1: -1
37GRHPRNM_012203.1: c.337G> TSNVLikely pathogenicChr na, -1: -1
38GRHPRNM_012203.1: c.214+2T> GSNVLikely pathogenicChr na, -1: -1
39GRHPRNM_012203.1(GRHPR): c.103delG (p.Asp35Thrfs)deletionPathogenicrs80356708GRCh37Chr 9, 37424861: 37424861
40GRHPRNM_012203.1(GRHPR): c.295C> T (p.Arg99Ter)SNVPathogenicrs119490108GRCh37Chr 9, 37426542: 37426542

Expression for genes affiliated with Hyperoxaluria, Primary, Type Ii

About this section
Search GEO for disease gene expression data for Hyperoxaluria, Primary, Type Ii.

Pathways for genes affiliated with Hyperoxaluria, Primary, Type Ii

About this section

GO Terms for genes affiliated with Hyperoxaluria, Primary, Type Ii

About this section

Sources for Hyperoxaluria, Primary, Type Ii

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet